Cargando...

Brexanolone for the treatment of patients with postpartum depression

On March 19, 2019, the United States Food and Drug Administration (FDA) approved Zulresso (brexanolone) for intravenous use for the treatment of postpartum depression (PPD) in adult women. The decision was based on three recent clinical trials following an FDA priority review and breakthrough therap...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Drugs Today (Barc)
Main Authors: Morrison, K.E., Cole, A.B., Thompson, S.M., Bale, T.L.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8033597/
https://ncbi.nlm.nih.gov/pubmed/31584571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1358/dot.2019.55.9.3040864
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!